Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)

NCT00314860 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00314860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00314860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
December 31, 2006
Enrollment
568 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome, restless legs syndrome (rls)